AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06609941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative nostril breathing
Description: Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.
Study NCT06609941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy
Description: Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:~Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.~Week 01 and week 02:~Patients will receive medication prescribed by pulmonologist.~Week 03 and week 04:~Patients will receive medication prescribed by pulmonologist.
Study NCT06609941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological therapy
Description: Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:~Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.~Week 01 and week 02:~Patients will receive medication prescribed by pulmonologist.~Week 03 and week 04:~Patients will receive medication prescribed by pulmonologist.
Study NCT05642585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral
Study NCT06609759 — intervention group
Intervention type: DRUG
Intervention: Standard chemotherapy regimen
Description: In terms of postoperative adjuvant treatment, treatment is based on the guideline standard treatment plan, which can be adjusted according to the doctor's experience.
Study NCT06262789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Return-to-work after cancer consultation
Description: The return-to-work after cancer consultation is carried out by a specialist in occupational pathology, who may be assisted by a psychologist and/or a nurse and/or a social worker, depending on the patient's personal situation. During this consultation, the team assesses the patient's medical situation, social situation and psychological situation. This consultation lasts approximatively 1 hour and aims to guide the patient in the different stages of return to work, to identify obstacles and apprehensions about return to work, to assess the patient's functional capacities and motivations, to provide information on the legislation, actors and tools for employment maintenance and to discuss possible adjustments of the work situation. The consultation provides a response to potential or encountered problems, directs the patient towards the actors and tools adapted to his/her situation.
Study NCT04907981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Novel coronavirus infection
Description: Using eye examination to judge whether novel coronavirus is infected or not.
Study NCT05055544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin
Description: a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A),
Study NCT05055544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bearberry
Description: a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
Study NCT06379165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Nanocrystal Injection
Description: 30 mg (1 mL), once daily, by intravenous infusion
Study NCT06379165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL Placebo, once daily, by intravenous infusion
Study NCT05109780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: My EMI, Emotional Well-being + self-applied online transdiagnostic treatment
Description: The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMI. In terms of monitoring, the My EMI, Emotional Well-being is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
Study NCT06396234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safe VLM and airway management
Description: Once the device is placed, following assessment, endotracheal intubation will be performed via the device.
Study NCT06396234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation using video laryngoscope
Description: Endotracheal intubation (size 7.0 mm) using video laryngoscope
Study NCT06396234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaCo VLM and airway management
Description: Once the device is placed, following assessment, endotracheal intubation will be performed via the device.
Study NCT04528914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet
Description: The low-FODMAP diet will contain the amount of FODMAPs that will not exceed the cut-offs for each FODMAP sugar per serving of food per sitting. Diets will be individually tailored by dietitian and delivered by a catering company (five meals each day).
Study NCT06728189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-NKT Cells treatment
Description: Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells Lymphodepleting regimen, Cyclophosphamide 250mg/m2 IV on day -5 to -3 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of CAR-NKT on day 0.~Potential CGC738 doses:~Dose level 1: 5.0×106 CAR- NKT cells/m2; Dose level 2: 1.5×107 CAR- NKT cells/m2; Dose level 3: 4.5×107 CAR- NKT cells/m2;
Study NCT05416216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WELL
Description: The WELL intervention is a multi-level, three-strategy program to promote the wellbeing of the ECE workforce.
Study NCT04941495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: 1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying.
Study NCT04941495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical proprioceptive training
Description: 1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying.~7. The patients wearing a cap with a laser pointer attached to it were seated three feet away from the target A, B and C. Start Chart A with a 3 cm, chart B 2cm and chart C 1cm narrow pathway were presented to the patients. The time taken by the patient to complete the pathway without any error was noted.
Study NCT05007522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen/Indomethacin
Description: 2 mg tablet, 75 mg SR tablet
Study NCT05007522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study NCT06290596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Hemostatic drug.
Study NCT06290596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Hemostatic drug.
Study NCT06290596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT06073808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft
Description: Dehydrated human amnion/chorion membrane (dHACMs) allografts have recently been identified as an easy-to-use treatment alternative for management of chronic wounds. These commercially available allografts contain concentrated cytokines and growth factors known to promote wound healing. Preclinical studies suggest that dHACM allografts provide a complex, biologically-driven mechanism to promote soft tissue repair and regeneration, including stimulation of mesenchymal stem cell migration and dermal fibroblast proliferation, establishment of a supportive inflammatory environment, and restoration of extracellular matrix integrity with positive tissue architecture remodeling. Clinically, dHACM allografts have been shown to improve healing time and wound closure rates in chronic wound patients. However, no study to date has evaluated the impact of dHACM allografts on nipple necrosis following NSM.
Study NCT06073808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Device
Description: Control device will be applied to non-experimental breast. Each patient will serve as their own control.
Study NCT05122728 — intervention group
Intervention type: OTHER
Intervention: Post-Concussion Neuromuscular Function and Musculoskeletal Injury Risk Assessment
Description: Participants will complete a comprehensive biomechanical and neuromuscular assessments to elucidate the underlying neuromuscular control mechanisms that may contribute to increased MSKI risk following concussion. Participants will also complete a battery of self-report psychosocial measures.~Biomechanical Dynamic Movement Assessments:~* Jump-Landing~* Single Leg Hop~* Anticipated Cut~* Gait - Single Task~* Gait - Dual Task~Strength and Voluntary Muscle Activation Assessments:~* Interpolated Twitch Technique~* Muscular Ramp Contraction~Sensory assessments:~* Proprioception - Closed Chain~* Passive Joint Repositioning~* Light Touch Sensation~Patient Reported Outcomes:~* Self-Reported Musculoskeletal Injuries~* National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function~* PROMIS Pain Interference~* PROMIS Depression~* PROMIS Anxiety~* Brief Resilience Scale (BRS)~* Tampa Scale of Kinesiophobia (TSK-11)
Study NCT06306209 — intervention group
Intervention type: OTHER
Intervention: Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management
Description: All participants enrolled in the study will receive Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management. Clinicians will be free to choose antidepressant medication, doses and drug combinations, including augmentations strategies and non-pharmacological treatments, which will follow standard clinical treatment guidelines for MDD.
Study NCT05839574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX monotherapy
Description: MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH), and subsequent hysteroscopic evacuation of products of conception (POC)
Study NCT05839574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX + letrozole add-on
Description: MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH) + Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0, and subsequent hysteroscopic evacuation of products of conception (POC)
Study NCT04725253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Nicotinamide, 1,5 gr per day for 7 days.
Study NCT04725253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tablets, 1 per day for 7 days.
Study NCT05753839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy±metastasectomy
Description: Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
Study NCT05753839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human-derived materials sampling
Description: Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, after induction therapy, and after 3 months of maintenance therapy.
Study NCT06436534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir Oral Capsule
Description: 2-week treatment phase：Ganciclovir capsules(250mg), take 2 capsules twice a day
Study NCT06436534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ganciclovir Simulant Oral Capsule
Description: 2-week treatment phase：Ganciclovir simulant capsules(0mg), take 2 capsules twice a day
Study NCT06436534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Nasal
Description: From screening phase to follow-up phase：Mometasone furoate aqueous nasal spray(50μg/spray), take 1 spray once a day
Study NCT06436534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone Nasal
Description: From screening phase to follow-up phase：Mometasone furoate aqueous nasal spray(50μg/spray), take 1 spray once a day
Study NCT04648319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558
Description: BMS-936558 followed by 30 grays of 3 to 5 fractions of high dose SBRT followed by monthly BMS-936558 until progression
Study NCT05057481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil 500mg
Description: MMF 2gram/day orally for 12 weeks
Study NCT05057481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 of rituximab given intravenously weekly for 4 weeks.
Study NCT05839171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music and mandala coloring
Description: Listening to music and coloring mandalas for women who have undergone embryo transfer and are waiting at home
Study NCT06028997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral and Sleep Hygiene Education with Mindfulness Intervention
Description: Education about good sleep hygiene practices and behavior advice to improve sleep based on current literature for 10-15 minutes/week followed by 50 minutes of yoga Nidra and breathing excersices
Study NCT06368258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red yeast rice
Description: Red yeast rice 160 mg (total monacolins 2.8 mg)
Study NCT06368258 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05430958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
Study NCT05430958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-9112
Description: INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
Study NCT05430958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
Study NCT05334251 — intervention group
Intervention type: OTHER
Intervention: combined spinal-epidural anesthesia
Description: Combined spinal and epidural anaesthesia is a regional anaesthetic technique, which combines the benefits of both spinal anaesthesia and epidural anaesthesia and analgesia. The spinal component gives a rapid onset of a predictable block. The indwelling epidural catheter gives the ability to provide long lasting analgesia and to titrate the dose given to the desired effect.
Study NCT05293067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: high-sensitive troponin
Description: Values of high-sensitive troponin would be measured as follows: 1) preoperatively - one day before the planned intervention and 2) postoperatively - 8 hours after the operation and the first day after the operation.
Study NCT04818619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometry test
Description: Blood samples will be stained with TIGIT by flow cytometry test
Study NCT04494074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Cooling
Description: External Cooling
Study NCT04099966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha beta depletion
Description: donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.
Study NCT05986370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar spinal manipulative therapy
Description: Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
Study NCT05986370 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham spinal manipulative therapy
Description: Sham spinal manipulative therapy (sham SMT), was designed to be structurally equivalent to SMT, i.e., to attend to the same body regions with the same amount of contact as well as to have the same number, frequency and length of sessions. SMT and sham SMT will be provided by the same treatment provider and will appear to be similarly tailored to the participants' condition. Sham SMT does not share the component of interest of SMT, i.e., the activation of deep high-threshold mechanoreceptors via high-velocity, low-amplitude thrusts applied to the spine. Yet, it shares all the other components not of interest in this study that may contribute to the placebo response, such as therapeutic alliance, contextual factors, physical touch, and expectations. Furthermore, deception will be used to balance expectations and enhance blinding.
Study NCT05986370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full spine spinal manipulative therapy
Description: Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
Study NCT06069817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: home treatment with HFNC after airway stent placement both for malignant and benignant central airway obstruction
Study NCT05247086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy
Description: After surgical wound closure we will apply negative pressure therapy
Study NCT06725082 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Humanized Type III Collagen Injection
Description: rhCOL3/saline will be injected around the tumor (at four points: outer upper, inner upper, outer lower, and inner lower) before surgery, with 500ul per site. After the surgical margin is confirmed to be safe by rapid frozen pathology during surgery, a second injection of 2ml will be administered around the surgical area skin (at points spaced along the skin incision), followed by routine tissue flap revision and suture.
Study NCT06725082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Type III Collagen Injection
Description: rhCOL3/saline will be injected around the tumor (at four points: outer upper, inner upper, outer lower, and inner lower) before surgery, with 500ul per site. After the surgical margin is confirmed to be safe by rapid frozen pathology during surgery, a second injection of 2ml will be administered around the surgical area skin (at points spaced along the skin incision), followed by routine tissue flap revision and suture.
Study NCT06069817 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nebulized normal saline
Description: home treatment with nebulized normal saline after airway stent placement both for malignant and benignant central airway obstruction
Study NCT05090735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPIP and TAP Block
Description: Injection of Bupivacaine 0.25% for SPIP Block and TAP Block.
Study NCT05090735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPIP Block
Description: Injection of Bupivacaine 0.25% for SPIP Block
Study NCT05182788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pressed candy
Description: consume 2 tablets per day for 8 weeks